Enliven Therapeutics Inc
Research Enliven Therapeutics Inc (ELVN) on Bullrun: market cap USD 4.47B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELVN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.47B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 32.49M
- Free cash flow-USD 18.63M
Valuation Snapshot
latest market cap is USD 4.47B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 103.70M | -USD 70.46M | n/a | -1.83 | USD 98.90M | USD 399.00K | USD 459.60M |
| FY2024 | USD 0 | -USD 89.00M | -USD 73.24M | n/a | -1.89 | USD 124.12M | USD 0 | USD 309.85M |
| FY2023 | n/a | -USD 71.58M | -USD 61.42M | n/a | -2.01 | USD 100.14M | USD 335.00K | USD 245.91M |
| FY2022 | n/a | -USD 37.66M | -USD 32.69M | n/a | -12.05 | USD 75.54M | USD 320.00K | -USD 76.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.47B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 915.38M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.10B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 570.37M | 4.3 | n/a | n/a |
About Enliven Therapeutics Inc
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Enliven Therapeutics Inc's market cap?
Enliven Therapeutics Inc's market capitalization is USD 4.47B.
What does Enliven Therapeutics Inc do?
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.